Tag: Cocrystal Pharma Stock

Business

Cocrystal Pharma Inc. (NASDAQ: COCP) Announces the Completion of the IND-enabling Studies with CC-42344 and Reports on a Possible Phase 1 Trial

There are more than 1 billion people infected with seasonal influenza annually in the US, according estimated by the World Health Organization (WHO). This translates to approximately 3 million to 5 million cases of severe illness. The situation has triggered the completion of IND-enabling studies for CC-42344 by Cocrystal Pharma […]